Literature DB >> 11343046

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

G M Nixon1, D S Armstrong, R Carzino, J B Carlin, A Olinsky, C F Robertson, K Grimwood.   

Abstract

OBJECTIVE: To determine the clinical consequences of acquiring Pseudomonas aeruginosa infection during early childhood in children with cystic fibrosis (CF).
DESIGN: Prospective, observational cohort study of 56 children with CF identified by newborn screening during 1990-92. Each child underwent an annual bronchial lavage during the first 2 to 3 years of life. Clinical outcome was determined at 7 years of age.
RESULTS: P aeruginosa infection was diagnosed in 24 (43%) cohort subjects. Four children died before 7 years of age, all of whom had been infected with a multi-resistant, mucoid strain of P aeruginosa (P =.04). In survivors, P aeruginosa infection was associated with significantly increased morbidity as measured by lower National Institutes of Health scores, greater variability in lung function, increased time in the hospital, and higher rates of recombinant human deoxyribonuclease therapy (P <.01). In this young CF cohort, best forced expiratory volume in 1 second was an insensitive measure of increased morbidity.
CONCLUSIONS: Acquisition of P aeruginosa was common by 7 years of age in this CF birth cohort and was associated with increased morbidity and mortality. An improved disease severity score would improve the evaluation and study of early CF lung disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343046     DOI: 10.1067/mpd.2001.112897

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  103 in total

Review 1.  Inhaled antibiotics in cystic fibrosis: what's new?

Authors:  Simon Langton Hewer
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

2.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

Review 3.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

4.  Viscous medium promotes cooperation in the pathogenic bacterium Pseudomonas aeruginosa.

Authors:  Rolf Kümmerli; Ashleigh S Griffin; Stuart A West; Angus Buckling; Freya Harrison
Journal:  Proc Biol Sci       Date:  2009-07-15       Impact factor: 5.349

Review 5.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

6.  Early airway infection, inflammation, and lung function in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood; Claire Wainwright
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

7.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

8.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

9.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

10.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.